Dublin, Jan. 24, 2024 (GLOBE NEWSWIRE) -- The "AMZ001 Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.
This report provides a detailed picture of the AMZ001 for osteoarthritis in the 6MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada, and Korea for the study period 2019 -2032 is provided in this report along with a detailed description of the AMZ001 for osteoarthritis.
The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the AMZ001 market forecast analysis for osteoarthritis in the 6MM, along with Canada and Korea, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in osteoarthritis.
Drug Summary
AMZ001 is a high-strength, discrete, odorless, noninvasive topical gel containing 3.06% diclofenac sodium. It is applied directly to the knee and designed as an FDA and EMA-approved proprietary technology. This nonsteroidal anti-inflammatory (NSAID) medication is intended to treat pain related to knee OA. As a topical product, AMZ001 is not absorbed into the gastrointestinal (GI) tract, reducing overall GI and systemic exposure, which could help reduce AEs compared to oral therapies.
Moreover, its higher drug strength (3.06%) combined with an efficient topical delivery system allows AMZ001 to effectively relieve localized pain with a single daily application (QD), reducing the total dose compared to other topical NSAID treatments. Other potential indications for AMZ001 include managing acute pain due to minor strains, sprains, and contusions, as well as treating low back pain, which is currently treated using opioids.
AMZ001 Analytical Perspective
In-depth AMZ001 Market Assessment
This report provides a detailed market assessment of AMZ001 for osteoarthritis in the six major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, along with Canada and Korea. This segment of the report provides forecasted sales data from 2024 to 2032.
AMZ001 Clinical Assessment
The report provides the clinical trials information of AMZ001 for osteoarthritis covering trial interventions, trial conditions, trial status, start and completion dates.
Report Highlights
- In the coming years, the market scenario for osteoarthritis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence AMZ001 dominance.
- Other emerging products for osteoarthritis are expected to give tough market competition to AMZ001 and launch of late-stage emerging therapies in the near future will significantly impact the market.
- A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of AMZ001 in osteoarthritis.
- This in-depth analysis of the forecasted sales data of AMZ001 from 2024 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the AMZ001 in osteoarthritis.
Key Questions
- What is the product type, route of administration and mechanism of action of AMZ001?
- What is the clinical trial status of the study related to AMZ001 in osteoarthritis and study completion date?
- What are the key collaborations, mergers and acquisitions, licensing and other activities related to the AMZ001 development?
- What are the key designations that have been granted to AMZ001 for osteoarthritis?
- What is the forecasted market scenario of AMZ001 for osteoarthritis?
- What are the forecasted sales of AMZ001 in the six major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, along with Canada and Korea?
- What are the other emerging products available and how are these giving competition to AMZ001 for osteoarthritis?
- Which are the late-stage emerging therapies under development for the treatment of osteoarthritis?
Key Topics Covered:
1. Report Introduction
2. AMZ001 Overview in Osteoarthritis
2.1. Product Detail
2.2. Clinical Development
2.2.1. Clinical studies
2.2.2. Clinical trials information
2.2.3. Safety and efficacy
2.3. Other Developmental Activities
2.4. Product Profile
3. Competitive Landscape (Marketed Therapies)
4. Competitive Landscape (Late-stage Emerging Therapies)
5. AMZ001 Market Assessment
5.1. Market Outlook of AMZ001 in Osteoarthritis
5.2. 6MM, Canada and Korea Analysis
5.2.1. Market Size of AMZ001 in the 6MM, Canada and Korea for Osteoarthritis
5.3. Country-wise Market Analysis
5.3.1. Market Size of AMZ001 in the United States for Osteoarthritis
5.3.2. Market Size of AMZ001 in Germany for Osteoarthritis
5.3.3. Market Size of AMZ001 in France for Osteoarthritis
5.3.4. Market Size of AMZ001 in Italy for Osteoarthritis
5.3.5. Market Size of AMZ001 in Spain for Osteoarthritis
5.3.6. Market Size of AMZ001 in the United Kingdom for Osteoarthritis
5.3.7. Market Size of AMZ001 in Canada for Osteoarthritis
5.3.8. Market Size of AMZ001 in Korea for Osteoarthritis
6. SWOT Analysis
7. Analysts' Views
8. Appendix
For more information about this report visit https://www.researchandmarkets.com/r/uctg5o
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
